Key result
New oral anticoagulants, PFO closure, and left atrial appendage ablation provide effective alternatives to traditional therapies for the prevention of cardioembolic stroke.
This review summarizes key advances in cardioembolic stroke prevention, emphasizing the shift toward new oral anticoagulants and emerging structural and metabolic interventions.
May expand options for cardioembolic stroke prevention; leaves open need for direct comparative trials.
Historically, because of the difficulty of using warfarin safely and effectively, many patients with cardioembolic stroke who should have been anticoagulated were instead given ineffective antiplatelet therapy (or no antithrombotic therapy). With the arrival of new oral anticoagulants that are not significantly more likely than aspirin to cause severe haemorrhage, everything has changed. Because antiplatelet agents are much less effective in preventing cardioembolic stroke, it is now more prudent to anticoagulate patients in whom cardioembolic stroke is strongly suspected. Recent advances include the recognition that intermittent atrial fibrillation is better detected with more prolonged monitoring of the cardiac rhythm, and that percutaneous closure of patent foramen ovale (PFO) may reduce the risk of stroke. However, because in most patients with stroke and PFO the PFO is incidental, this should be reserved for patients in whom paradoxical embolism is likely. A high shunt grade on transcranial Doppler saline studies, and clinical clues to paradoxical embolism, can help in appropriate selection of patients for percutaneous closure. For patients with atrial fibrillation who cannot be anticoagulated, ablation of the left atrial appendage is an emerging option. It is also increasingly recognised that high levels of homocysteine, often due to undiagnosed metabolic deficiency of vitamin B 12 , markedly increase the risk of stroke in atrial fibrillation, and that B vitamins (folic acid and B 12 ) do prevent stroke by lowering homocysteine. However, with regard to B 12 , methylcobalamin should probably be used instead of cyanocobalamin. Many important considerations for judicious application of therapies to prevent cardioembolic stroke are discussed.
No takes yet. Share an insight, caveat, or question.
J. David Spence (2018) conducted a review in Cardioembolic stroke. New oral anticoagulants, PFO closure, and left atrial appendage ablation vs. Historical therapies (warfarin, antiplatelet therapy) was evaluated. New oral anticoagulants, PFO closure, and left atrial appendage ablation provide effective alternatives to traditional therapies for the prevention of cardioembolic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: